Speciality Medicines Private Limited

Speciality Medicines Private Limited (SMPL) is a pharmaceutical company based in Ahmedabad, Gujarat, India. Incorporated on February 5, 2021, under the Corporate Identification Number (CIN) U85300GJ2021PTC120022, SMPL operates as a private limited company. The company is owned by directors Sumit Babubhai Goyani and Parthkumar Babulal Goyani. Its registered office is located at H-401, Silver Stroke Apartment, Bopal, Ahmedabad, Gujarat, 380058, India. SMPL specializes in the wholesale trading and export of pharmaceutical products, focusing on specialty medicines. The company has experienced significant growth, with an annual turnover ranging between ₹25 to ₹100 crore, and employs between 26 to 50 people. In June 2024, SMPL transitioned from a private limited to a public limited company, adopting the name Speciality Medicines Limited.

SMPL operates state-of-the-art manufacturing facilities across multiple locations in India. These facilities are WHO-GMP certified, ensuring adherence to global quality standards. The company specializes in the production of oral solids, liquid formulations, specialty products, creams, and ointments. Additionally, SMPL maintains modern, temperature-controlled warehouses in various regions, including India and Africa, to support its distribution and export operations.

The leadership team at SMPL is headed by Managing Director Parth Goyani, who has been instrumental in the company's strategic direction and growth. The Chief Financial Officer (CFO) and other key executives are not publicly disclosed. The company's board of directors includes Sumit Babubhai Goyani and Parthkumar Babulal Goyani, who play pivotal roles in overseeing operations and strategic initiatives.

SMPL has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company holds WHO-GMP certification, which facilitates market access in these regions. While specific regulatory filings and approvals in these markets are not publicly disclosed, SMPL's adherence to international quality standards positions it favorably for market entry and compliance.

SMPL has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's WHO-GMP certification enhances its credibility and facilitates access to these regions. SMPL exports to over 23 countries, including Sri Lanka, the United Kingdom, Myanmar, Saudi Arabia, and Ethiopia, indicating a robust presence in these emerging markets.

SMPL's geographic strategy demonstrates a diversified approach, with exports to over 23 countries across Africa, Europe, the Middle East, and Southeast Asia. This diversification mitigates concentration risk and positions the company to leverage growth opportunities in various regions. The strategic direction focuses on expanding market presence and enhancing global distribution capabilities.

Specific details regarding SMPL's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's WHO-GMP certification suggests compliance with international manufacturing standards, which is a prerequisite for FDA approvals.

SMPL holds WHO-GMP certification, indicating compliance with the World Health Organization's Good Manufacturing Practices. This certification is recognized by the European Union and facilitates market access in EU member states. Specific details regarding EU GMP certificates and EDQM status are not publicly disclosed.

SMPL operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses and approvals from state drug controllers, ensuring compliance with Indian pharmaceutical regulations. Specific details regarding export No Objection Certificates (NOCs) are not publicly available.

As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to SMPL. The company's adherence to WHO-GMP standards suggests a commitment to maintaining high-quality manufacturing practices.

SMPL operates in a competitive pharmaceutical market, with key competitors including AmerisourceBergen, Entero Healthcare, Keimed, Sandor Medicaids, and Mahaveer Medi Sales. While specific market share comparisons are not publicly available, SMPL's focus on specialty medicines and adherence to international quality standards position it as a competitive player in the industry.

SMPL's key differentiators include its WHO-GMP certification, which ensures compliance with international manufacturing standards, and its diversified product portfolio encompassing oncology, neurology, cardiology, anti-virals, hepatitis, antifungals, injections, life-saving medicines, and vaccines. The company's modern, temperature-controlled warehouses and global distribution network further enhance its competitive advantage.

SMPL's current strategic direction focuses on the wholesale trading and export of specialty medicines, with an emphasis on oncology, neurology, cardiology, and other therapeutic areas. The company's future outlook includes expanding its global presence, enhancing manufacturing capabilities, and exploring opportunities in biosimilars and contract development and manufacturing organizations (CDMO) to diversify its portfolio and revenue streams.

SMPL has demonstrated a strong track record in the pharmaceutical industry, with an annual turnover ranging between ₹25 to ₹100 crore and employing between 26 to 50 people. The company's adherence to WHO-GMP standards and its diversified product portfolio indicate reliability and consistency in its operations. SMPL's global distribution network and modern, temperature-controlled warehouses further underscore its commitment to quality and customer satisfaction.

Importers should verify the following certifications when considering SMPL as a supplier:

• WHO-GMP Certification: Ensures compliance with international manufacturing standards. Verification can be obtained by contacting the World Health Organization or reviewing the company's official documentation.

• EU GMP Certification: Facilitates market access in EU member states. Verification can be obtained by contacting the European Medicines Agency or reviewing the company's official documentation.

• ISO Certification: Indicates adherence to international quality management standards. Verification can be obtained by contacting the International Organization for Standardization or reviewing the company's official documentation.

When conducting due diligence on SMPL, consider the following steps:

• Verify Certifications: Confirm the validity of WHO-GMP, EU GMP, and ISO certifications through the respective certifying bodies.

• Review Regulatory Compliance: Assess the company's compliance with CDSCO and other relevant regulatory authorities.

• Evaluate Financial Health: Review financial statements and annual reports to assess the company's financial stability.

• Assess Supply Chain Reliability: Evaluate the company's supply chain processes, including sourcing, manufacturing, and distribution capabilities.

• Check References: Obtain feedback from existing clients and partners regarding the company's performance and reliability.

Red flags to watch for include expired or invalid certifications, regulatory violations, financial inconsistencies, and negative feedback from clients or partners. Recommended pre-order checks include requesting product samples, reviewing quality control processes, and conducting site visits to manufacturing facilities.